
Home - Syndax
2025年3月3日 · At Syndax, we are advancing the next generation of targeted treatments with the goal of realizing a future in which people with cancer live longer and better than ever before. …
Pipeline - Syndax
Syndax anticipates submitting a supplemental NDA (sNDA) based on this positive data from the pivotal AUGMENT-101 trial of revumenib in adults and pediatric patients with NPM1m AML in …
About Us - Syndax
Syndax’s mission is to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients by drawing on the newest scientific research and …
Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance
Find the latest Syndax Pharmaceuticals, Inc. (SNDX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Press Releases - Syndax Pharmaceuticals, Inc.
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A …
Investors | Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include …
Syndax Announces Positive Pivotal Topline Results from Relapsed …
2024年11月12日 · Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline …
Syndax Announces Participation in March Investor Conferences
2025年2月25日 · Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the …
US FDA approves Syndax's blood cancer drug | Reuters
2024年11月15日 · The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and pediatric patients with a type of blood …
Syndax Announces Positive Pivotal Topline Results from Relapsed …
2024年11月12日 · Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today …
- 某些结果已被删除